NATCO Pharma’s Subsidiary Invests $8 Million in eGenesis

On September 4, 2024, NATCO Pharma Limited announced that its wholly-owned Canadian subsidiary, NATCO Pharma (Canada) Inc., has invested US$ 8 million in eGenesis, Inc., a leading biotechnology firm specialising in xenotransplantation. eGenesis is at the forefront of developing human-compatible organs for transplantation.

In March 2024, eGenesis achieved a significant milestone by performing the world’s first porcine kidney transplant in a living patient, an operation approved by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway.

eGenesis is pioneering the development of transplantable organs using genome engineering. Its unique EGEN™ Platform addresses cross-species molecular incompatibilities and viral risks through genetic modifications. This groundbreaking approach aims to address the global organ shortage and transform organ failure treatment. eGenesis is advancing research in kidney, acute liver failure, and heart transplants.

Commenting on this development, the Vice Chairman and CEO of NATCO Pharma Limited, Rajeev Nannapaneni, said, “We are excited to get involved with eGenesis, Inc. with respect to their pioneering work in xenotransplantation. We agree with the vision of eGenesis that xenotransplantation technology has the potential to end the global transplant shortage and transform the treatment of organ failure by eliminating waitlist mortality.”

“We are thrilled to welcome NATCO as an investor. Their support will be used in advancing our research and bringing our innovative therapies to market,” said Mike Curtis, CEO of eGenesis, Inc.

About NATCO Pharma Limited

NATCO Pharma Limited is a vertically integrated pharmaceutical company. Emphasising research and development, NATCO Pharma is committed to providing high-quality, affordable medications to patients globally.

On September 4, 2024, the share price of NATCO Pharma Ltd opened at ₹1,518.85, touching the day’s low at ₹1,503.05, as of 11:33 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.